MSA treatment significantly downregulated TGF-β1, PD-L1, and VEGF in a dose- and time-dependent manner in both non-sarcomatoid and sarcomatoid ccRCC cell lines. The gene discussed is CD274; the disease is nonpapillary renal cell carcinoma.